We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Omrix Biopharmaceuticals announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, whereby the parties will perform collaborative research to develop new antibody-based therapeutics for the treatment of avian influenza.
Dutch biotechnology company Crucell announced it has secured a $ 16.2 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. NIH, for the design and development of an HIV vaccine.
China Pharma Holdings announced it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its granisetron hydrochloride injection product.
Eugene Science Inc. has signed a distribution agreement for its cholesterol-lowering CholCare softgel capsules with Seoul, Korea-based NC Trading Company.
Bilcare Limited, India's leading pharma company in the drug discovery-to-market value chain, has acquired DHP Limited, a UK-based clinical trials service provider.
Pfizer Inc announced it has entered into an agreement to acquire PowderMed Ltd., a privately held U.K. company specializing in the emerging science of DNA-based vaccines.
Merck is facing thousands of lawsuits related to Vioxx Hundreds of British patients who claim they had heart attacks after taking the drug Vioxx have lost the right to fight for compensation in the US.
The St. John's Medical College in Bangalore, YRG Care Chennai and the National AIDS Research Institute in Pune have been selected as part of a global research initiative to test the efficacy of microbicides in the prevention of HIV.
Drug makers Bristol-Myers Squibb Co., Gilead Sciences Inc., and Merck & Co. said Monday that they filed a marketing application with European regulators to get the once-a-day single tablet HIV drug Atripla approved.
The U.S. NIH will award almost $700 million in research grants to 12 academic health centers between Oct. 1, 2006, and June 30, 2011, roughly $100 million of that in the nine-month period ending June 30, 2007.